Leukemia & Lymphoma, Volume 59, Issue 7 (2018)

Browse this journal
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Leukemia & Lymphoma, Volume 59, Issue 7 (2018)

See all volumes and issues
Vol 65, 2024 Vol 64, 2023 Vol 63, 2022 Vol 62, 2021 Vol 61, 2020 Vol 60, 2019 Volume 59, 2018 Vol 58, 2017 Vol 57, 2016 Vol 56, 2015 Vol 55, 2014 Vol 54, 2013 Vol 53, 2012 Vol 52, 2011 Vol 51, 2010 Vol 50, 2009 Vol 49, 2008 Vol 48, 2007 Vol 47, 2006 Vol 46, 2005 Vol 45, 2004 Vol 44, 2003 Vol 43, 2002 Vol 42, 2001 Vol 41, 2001 Vol 40, 2000-2001 Vol 39, 2000 Vol 38, 2000 Vol 37, 2000 Vol 36, 1999-2000 Vol 35, 1999 Vol 34, 1999 Vol 33, 1999 Vol 32, 1998-1999 Vol 31, 1998 Vol 30, 1998 Vol 29, 1998 Vol 28, 1997-1998 Vol 27, 1997 Vol 26, 1997 Vol 25, 1997 Vol 24, 1996-1997 Vol 23, 1996 Vol 22, 1996 Vol 21, 1996 Vol 20, 1995-1996 Vol 19, 1995 Vol 18, 1995 Vol 17, 1995 Vol 16, 1995 Vol 15, 1995 Vol 16, 1995 Vol 15, 1995 Vol 14, 1994 Vol 13, 1994 Vol 12, 1993-1994 Vol 11, 1993 Vol 10, 1993 Vol 9, 1993 Vol 8, 1992 Vol 7, 1992 Vol 6, 1991-1992 Vol 5, 1991 Vol 4, 1991 Vol 3, 1990-1991 Vol 2, 1990 Vol 1, 1989-1990
Download citations Download PDFs

Commentary

The price of success-health economics of personalized diffuse large B-cell lymphoma treatment
Piers Blombery, Jennifer Lickiss & Michael Dickinson
Pages: 1517-1519
Published online: 07 Dec 2017
First Page PreviewforThe price of success-health economics of personalized diffuse large B-cell lymphoma treatment | Full Text | References | PDF (304.9 KB) | Supplemental
  • 221 Views
  • 1 CrossRef citations
  • 0Altmetric
FGFR1 rearranged hematological neoplasms – molecularly defined and clinically heterogeneous
Mrinal M. Patnaik, Rhett P. Ketterling & Ayalew Tefferi
Pages: 1520-1522
Published online: 31 Jan 2018
First Page PreviewforFGFR1 rearranged hematological neoplasms – molecularly defined and clinically heterogeneous | Full Text | References | PDF (455.4 KB) | Supplemental
  • 364 Views
  • 6 CrossRef citations
  • 0Altmetric

Review

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI
Giuseppe Saglio & Elias Jabbour
Pages: 1523-1538
Published online: 03 Oct 2017
AbstractforFirst-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI | Full Text | References | PDF (1.1 MB) | Supplemental
  • 6069 Views
  • 20 CrossRef citations
  • 0Altmetric
Open Access
Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse
Katherine D. Cummins & Saar Gill
Pages: 1539-1553
Published online: 13 Sep 2017
AbstractforAnti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse | Full Text | References | PDF (2 MB) | Supplemental
  • 1479 Views
  • 28 CrossRef citations
  • 0Altmetric
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors
Chloe Pek Sang Tang, Julie McMullen & Constantine Tam
Pages: 1554-1564
Published online: 13 Sep 2017
AbstractforCardiac side effects of bruton tyrosine kinase (BTK) inhibitors | Full Text | References | PDF (1.1 MB) | Supplemental
  • 1787 Views
  • 32 CrossRef citations
  • 0Altmetric
Regulation of MAPK signaling and implications in chronic lymphocytic leukemia
Ashima Shukla, Vipul Shukla & Shantaram S. Joshi
Pages: 1565-1573
Published online: 07 Sep 2017
AbstractforRegulation of MAPK signaling and implications in chronic lymphocytic leukemia | Full Text | References | PDF (795.3 KB) | Supplemental
  • 561 Views
  • 10 CrossRef citations
  • 0Altmetric

Emerging Drug Profile

Enhancer of zeste homolog 2 (EZH2) inhibitors
Nitya Gulati, Wendy Béguelin & Lisa Giulino-Roth
Pages: 1574-1585
Published online: 23 Feb 2018
AbstractforEnhancer of zeste homolog 2 (EZH2) inhibitors | Full Text | References | PDF (1.2 MB) | Supplemental
  • 2198 Views
  • 108 CrossRef citations
  • 0Altmetric

Original Article: Clinical

Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital
Mary Gleeson, Clare Peckitt, David Cunningham, Adam Gibb, Eliza A. Hawkes, Morgan Back, Binnaz Yasar, Kate Foley, Rebecca Lee, Joanna Dash, Hannah Johnson, Catherine O’Hara, Andrew Wotherspoon, Ayoma Attygalle, Lia Menasce, Patrick Shenjere, Mike Potter, Mark E. Ethell, Claire Dearden, John Radford, Ian Chau & Kim Linton
Pages: 1586-1595
Published online: 09 Nov 2017
AbstractforOutcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital | Full Text | References | PDF (1.4 MB) | Supplemental
  • 444 Views
  • 7 CrossRef citations
  • 0Altmetric
Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma
Deeter R. Neumann, Bernard L. Marini, Tycel J. Phillips, Ryan A. Wilcox, Tera L. Mayer, Anna Brown & Anthony J. Perissinotti
Pages: 1596-1605
Published online: 06 Nov 2017
AbstractforPegasparaginase silent inactivation during therapy for NK/T cell lymphoma | Full Text | References | PDF (837.3 KB) | Supplemental
  • 356 Views
  • 2 CrossRef citations
  • 0Altmetric
Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14)
Kuniaki Itoh, Tadahiko Igarashi, Hiroyuki Irisawa, Nobuyuki Aotsuka, Shinichi Masuda, Yoshikazu Utsu, Hideki Tsujimura, Kunihiro Tsukasaki & Hisashi Wakita
Pages: 1606-1613
Published online: 30 Oct 2017
AbstractforRandomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14) | Full Text | References | PDF (687.6 KB) | Supplemental
  • 382 Views
  • 0 CrossRef citations
  • 0Altmetric
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome
Daniela Steinbrecher, Billy Michael Chelliah Jebaraj, Christof Schneider, Jennifer Edelmann, Florence Cymbalista, Véronique Leblond, Alain Delmer, Stefan Ibach, Eugen Tausch, Annika Scheffold, Johannes Bloehdorn, Michael Hallek, Peter Dreger, Hartmut Döhner & Stephan Stilgenbauer
Pages: 1614-1623
Published online: 24 Oct 2017
AbstractforTelomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome | Full Text | References | PDF (1.5 MB) | Supplemental
  • 493 Views
  • 9 CrossRef citations
  • 0Altmetric
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials
Michael J. Burke, Meenakshi Devidas, Kelly Maloney, Anne Angiolillo, Reuven Schore, Kimberly Dunsmore, Eric Larsen, Len A. Mattano Jr., Wanda Salzer, Stuart S. Winter, William Carroll, Naomi J. Winick, Mignon L. Loh, Elizabeth Raetz, Stephen P. Hunger & Archie Bleyer
Pages: 1624-1633
Published online: 08 Nov 2017
AbstractforSevere pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials | Full Text | References | PDF (993 KB) | Supplemental
  • 544 Views
  • 31 CrossRef citations
  • 0Altmetric
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
Josep-Maria Ribera, Mireia Morgades, Pau Montesinos, Rodrigo Martino, Pere Barba, Beatriz Soria, Arancha Bermúdez, María-José Moreno, José González-Campos, Susana Vives, Cristina Gil, Eugenia Abella, Ramon Guàrdia, Daniel Martínez-Carballeira, Pilar Martínez-Sánchez, María-Luz Amigo, Santiago Mercadal, Alfons Serrano, Aurelio López-Martínez, Ferran Vall-Llovera, María-José Sánchez-Sánchez, María-Jesús Peñarrubia, María Calbacho, Jose-Angel Méndez, Juan Bergua, Antonia Cladera, Mar Tormo, Daniel García-Belmonte, Evarist Feliu, Juana Ciudad, Alberto Orfao & on behalf of the PETHEMA Group, Spanish Society of Hematology
Pages: 1634-1643
Published online: 22 Nov 2017
AbstractforEfficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia | Full Text | References | PDF (1,021.4 KB) | Supplemental
  • 454 Views
  • 10 CrossRef citations
  • 0Altmetric
Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation
Anand Tandra, Fahrettin Covut, Brenda Cooper, Richard Creger, Lauren Brister, Bernadette McQuigg, Paolo Caimi, Ehsan Malek, Ben Tomlinson, Hillard M. Lazarus, Folashade Otegbeye, Merle Kolk, Marcos de Lima & Leland Metheny
Pages: 1644-1651
Published online: 04 Dec 2017
AbstractforLow dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation | Full Text | References | PDF (872.8 KB) | Supplemental
  • 292 Views
  • 10 CrossRef citations
  • 0Altmetric
Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission
Wei-Yang Li, Ying Wang, Su-Ning Chen, Hui-Ying Qiu, Zheng-Zheng Fu, De-Pei Wu & Ai-Ning Sun
Pages: 1652-1658
Published online: 18 Oct 2017
AbstractforConsolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission | Full Text | References | PDF (658 KB) | Supplemental
  • 184 Views
  • 5 CrossRef citations
  • 0Altmetric
Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia
Mathilde Ruggiu, Florence Oberkampf, David Ghez, Pascale Cony-Makhoul, Florence Beckeriche, Isabelle Cano, Anne L. Taksin, Omar Benbrahim, Stéphanie Ghez, Hassan Farhat, Sophie Rigaudeau, Noémie de Gunzburg, Diane Lara, Christine Terre, Victoria Raggueneau, Isabel Garcia, Marc Spentchian, Stéphane De Botton & Philippe Rousselot
Pages: 1659-1665
Published online: 28 Nov 2017
AbstractforAzacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia | Full Text | References | PDF (670 KB) | Supplemental
  • 503 Views
  • 14 CrossRef citations
  • 0Altmetric
A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma
Pritesh Patel, Annie L. Oh, Matthew Koshy, Karen Sweiss, Santosh L. Saraf, John G. Quigley, Irum Khan, Nadim Mahmud, Eileen Hacker, Howard Ozer, David J. Peace, Ralph R. Weichselbaum, Bulent Aydogan & Damiano Rondelli
Pages: 1666-1671
Published online: 25 Oct 2017
AbstractforA phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma | Full Text | References | PDF (570.5 KB) | Supplemental
  • 310 Views
  • 19 CrossRef citations
  • 0Altmetric
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
Paolo Strati, Guilin Tang, Dzifa Y. Duose, Saradhi Mallampati, Rajyalakshmi Luthra, Keyur P. Patel, Mohammad Hussaini, Abu-Sayeef Mirza, Rami S. Komrokji, Stephen Oh, John Mascarenhas, Vesna Najfeld, Vivek Subbiah, Hagop Kantarjian, Guillermo Garcia-Manero, Srdan Verstovsek & Naval Daver
Pages: 1672-1676
Published online: 09 Nov 2017
AbstractforMyeloid/lymphoid neoplasms with FGFR1 rearrangement | Full Text | References | PDF (763.4 KB) | Supplemental
  • 1347 Views
  • 34 CrossRef citations
  • 0Altmetric

Original Article: Research

Identifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in multiple myeloma
Raman Kumar, Rehan Khan, Nidhi Gupta, Tulika Seth, Atul Sharma, Mani Kalaivani & Alpana Sharma
Pages: 1677-1689
Published online: 18 Oct 2017
AbstractforIdentifying the biomarker potential of telomerase activity and shelterin complex molecule, telomeric repeat binding factor 2 (TERF2), in multiple myeloma | Full Text | References | PDF (1.8 MB) | Supplemental
  • 281 Views
  • 10 CrossRef citations
  • 0Altmetric
Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing
Jiangyan Yu, Željko Antić, Simon V. van Reijmersdal, Alexander Hoischen, Edwin Sonneveld, Esmé Waanders & Roland P. Kuiper
Pages: 1690-1699
Published online: 23 Oct 2017
AbstractforAccurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing | Full Text | References | PDF (2.6 MB) | Supplemental
  • 410 Views
  • 3 CrossRef citations
  • 0Altmetric
Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma
Qiushi Chen, Ashley D. Staton, Turgay Ayer, Daniel A. Goldstein, Jean L. Koff & Christopher R. Flowers
Pages: 1700-1709
Published online: 25 Oct 2017
AbstractforExploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma | Full Text | References | PDF (1.2 MB) | Supplemental
  • 931 Views
  • 23 CrossRef citations
  • 0Altmetric
Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines
Darius Juskevicius, Anne Müller, Hind Hashwah, Pontus Lundberg, Alexandar Tzankov & Thomas Menter
Pages: 1710-1716
Published online: 18 Oct 2017
AbstractforCharacterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines | Full Text | References | PDF (1.6 MB) | Supplemental
  • 893 Views
  • 9 CrossRef citations
  • 0Altmetric

Letter to the Editor

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells
Mark B. Geyer, Shwetha H. Manjunath, Andrew G. Evans, Jae H. Park, Marco L. Davila, Corey S. Cutler, Xiuyan Wang, Yongzeng Wang, Brigitte Senechal, Isabelle Rivière, Michel Sadelain, Jane L. Liesveld & Renier J. Brentjens
Pages: 1717-1721
Published online: 18 Oct 2017
First Page PreviewforConcurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells | Full Text | References | PDF (1.5 MB) | Supplemental
  • 631 Views
  • 5 CrossRef citations
  • 0Altmetric
Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule
Christine Greil, Gabriele Ihorst, Chrissoula Kiote-Schmidt, Steffi Hildenbeutel, Katja Kühbach, Roland Bosse, Justus Duyster, Monika Engelhardt & Ralph Wäsch
Pages: 1722-1725
Published online: 30 Oct 2017
First Page PreviewforStem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule | Full Text | References | PDF (514.8 KB) | Supplemental
  • 340 Views
  • 3 CrossRef citations
  • 0Altmetric
A mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor β agonists toward tumor burden
Simon Body, Anna Esteve-Arenys, Clara Recasens-Zorzo, Xavier Troussard, Gaël Roué & Brigitte Sola
Pages: 1726-1729
Published online: 22 Nov 2017
First Page PreviewforA mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor β agonists toward tumor burden | Full Text | References | PDF (1 MB) | Supplemental
  • 258 Views
  • 2 CrossRef citations
  • 0Altmetric
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia
Satyen Harish Gohil, Nicola Maciocia, Pip Patrick, Thomas Roberts, Nicholas Counsell, Paul Smith, Laura Clifton-Hadley, Kate Cwynarski, Andrew Pettitt & Amit Chunilal Nathwani
Pages: 1730-1733
Published online: 22 Nov 2017
First Page PreviewforLenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia | Full Text | References | PDF (319.1 KB) | Supplemental
  • 245 Views
  • 0 CrossRef citations
  • 0Altmetric
Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient
Orsola Vitagliano, Fabio Trastulli, Fabiana Cacace, Stefania Leone, Mara Memoli, Giulia Scalia, Marianna Notarangelo, Ciro G. Mainolfi, Amalia De Renzo & Fabrizio Pane
Pages: 1734-1737
Published online: 11 Oct 2017
First Page PreviewforIbrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient | Full Text | References | PDF (563.9 KB) | Supplemental
  • 328 Views
  • 3 CrossRef citations
  • 0Altmetric
Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia
Rino Sato, Jillian Jacob & Sameh Gaballa
Pages: 1738-1741
Published online: 30 Oct 2017
First Page PreviewforRapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia | Full Text | References | PDF (661.3 KB) | Supplemental
  • 325 Views
  • 3 CrossRef citations
  • 0Altmetric
Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis
Riwa Sakr, Aline Renneville, Veronique Saada, Sophie Cotteret, Jean-Edouard Martin, Nathalie Droin, Dorothée Selimoglu-Buet, Benjamin Besse, Antoine Hollebecque, Christophe Marzac, Florence Pasquier, Jean-Baptiste Micol, Stéphane De Botton, Olivier Mir, Eric Solary & Christophe Willekens
Pages: 1742-1745
Published online: 08 Nov 2017
First Page PreviewforNext-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis | Full Text | References | PDF (419.2 KB) | Supplemental
  • 277 Views
  • 6 CrossRef citations
  • 0Altmetric
Drugging DNA repair to target T-ALL cells
Yashodhara Dasgupta, Konstantin Golovine, Margaret Nieborowska-Skorska, Li Luo, Ksenia Matlawska-Wasowska, Charles G. Mullighan & Tomasz Skorski
Pages: 1746-1749
Published online: 08 Nov 2017
First Page PreviewforDrugging DNA repair to target T-ALL cells | Full Text | References | PDF (1 MB) | Supplemental
  • 1177 Views
  • 35 CrossRef citations
  • 0Altmetric

Correspondence

Allogeneic stem cell transplantation as a risk factor for recurrent melanoma
Hannah Stevens, Kavita Raj, Michael Ashby & Andrew Grigg
Pages: 1750-1752
Published online: 31 Oct 2017
First Page PreviewforAllogeneic stem cell transplantation as a risk factor for recurrent melanoma | Full Text | References | PDF (253.4 KB) | Supplemental
  • 119 Views
  • 1 CrossRef citations
  • 0Altmetric

Letter to the Editor

Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?
Brady E. Beltran, Pilar Quiñones, Gadwyn Sanchez, Antonio Paredes, Celia Moises, Esther Cotrina, Carlos A. Torres-Cabala, Roberto N. Miranda & Jorge J. Castillo
Pages: 1753-1755
Published online: 30 Oct 2017
First Page PreviewforPrimary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? | Full Text | References | PDF (1.4 MB) | Supplemental
  • 133 Views
  • 4 CrossRef citations
  • 0Altmetric
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy
Emmanuelle Le Ray, Lisa Belin, Corine Plancher, Philippe Anract, Antoine Babinet, Valérie Dumaine, Jérôme Tamburini, Bénédicte Deau Fischer, Lise Willems, Leonardo Magro, Thierry Facon, Xavier Leleu, Didier Bouscary & Youlia M. Kirova
Pages: 1756-1758
Published online: 31 Oct 2017
First Page PreviewforOur experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy | Full Text | References | PDF (288 KB) | Supplemental
  • 290 Views
  • 6 CrossRef citations
  • 0Altmetric
Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data
Paras Vakharia, Beatrice Nardone, William Budris, Kevin Hoshizaki, Olga Frankfurt & Dennis P. West
Pages: 1759-1761
Published online: 08 Nov 2017
First Page PreviewforBlinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data | Full Text | References | PDF (309.3 KB) | Supplemental
  • 413 Views
  • 2 CrossRef citations
  • 0Altmetric
Breakthrough Saprochaete Capitata infections among patients with hematological malignancies
Nitin Bansal, Vidya Devarajan, Abdul Ghafur K.Nandini Sethuraman & Lakshmi Sree V.
Pages: 1762-1763
Published online: 07 Dec 2017
CitationforBreakthrough Saprochaete Capitata infections among patients with hematological malignancies | Full Text | References | PDF (237.4 KB) | Supplemental
  • 152 Views
  • 4 CrossRef citations
  • 0Altmetric

Correspondence

Cardio-oncology in multiple myeloma: is it time for a specific focus?
Salvatrice Mancuso, Melania Carlisi, Matteo Sarocchi, Mariasanta Napolitano & Sergio Siragusa
Pages: 1764-1766
Published online: 31 Oct 2017
CitationforCardio-oncology in multiple myeloma: is it time for a specific focus? | Full Text | References | PDF (764.6 KB) | Supplemental
  • 193 Views
  • 5 CrossRef citations
  • 0Altmetric

Explore articles

Explore the most recently published articles

Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia
Jennifer Marvin-Peek et al.
Article | Published online: 15 May 2024
Mitigating time toxicity in lymphoma and multiple myeloma
Mengyang Di et al.
Review Article | Published online: 15 May 2024
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure
Fabien Despas et al.
Letter to the Editor | Published online: 15 May 2024
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry
Paul Wadsworth et al.
Letter to the Editor | Published online: 15 May 2024
View all latest articles